OLMA Olema Pharmaceuticals, Inc.: Earnings per share for the last 12 months

Olema Pharmaceuticals develops innovative breast cancer treatments targeting estrogen receptors. This annual EPS TTM chart on GURU.Markets shows that -29.90 is the current metric value. The company is driven by the elite of molecular biology with a powerful scientific foundation, yet high development costs and the uncertainty of clinical trial outcomes create significant financial risks.
OLMA (Olema Pharmaceuticals, Inc.): analytical breakdowns and indicator data

By developing a specialized breast cancer therapy ecosystem, Olema Pharmaceuticals (OLMA) is creating high barriers to entry for competitors through unique clinical protocols. Analyzing the rolling annual change in EPS allows for the removal of accounting anomalies from profit trends, revealing the actual growth rate of earnings per share and mitigating the risk of business overvaluation during periods of temporary margin smoothing.